LTRN vs. LPTX, BTAI, PRPH, GRTS, TRVI, VTYX, BMEA, GBIO, GTHX, and RENB
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), ProPhase Labs (PRPH), Gritstone bio (GRTS), Trevi Therapeutics (TRVI), Ventyx Biosciences (VTYX), Biomea Fusion (BMEA), Generation Bio (GBIO), G1 Therapeutics (GTHX), and Renovaro (RENB). These companies are all part of the "medical" sector.
Leap Therapeutics (NASDAQ:LPTX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
Leap Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
Leap Therapeutics currently has a consensus target price of $10.40, suggesting a potential upside of 372.73%. Given Lantern Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Leap Therapeutics is more favorable than Lantern Pharma.
Lantern Pharma has lower revenue, but higher earnings than Leap Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lantern Pharma had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 2 mentions for Lantern Pharma and 1 mentions for Leap Therapeutics. Lantern Pharma's average media sentiment score of 1.87 beat Leap Therapeutics' score of 1.44 indicating that Leap Therapeutics is being referred to more favorably in the media.
Leap Therapeutics received 279 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 68.79% of users gave Leap Therapeutics an outperform vote.
Leap Therapeutics' return on equity of -41.17% beat Lantern Pharma's return on equity.
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 11.3% of Leap Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Leap Therapeutics beats Lantern Pharma on 9 of the 16 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
